|
"chiu cf"的相關文件
顯示項目 1-25 / 115 (共5頁)
1 2 3 4 5 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-10-28 |
Deglycosylated PD-L1 is a biomarker for immune checkpoint blockade response: A real-world study in breast cancer patients in Taiwan
|
Wang, SC;Shen, YC;Pan, MR;Ou-Yang, F;Liao, TY;Liu, LC;Rau, KM;Lu, LS;Huang, CC;Dai, MS;Lu, YS;Chang, HW;Chang, H;Chang, KP;Wang, J;Tsai, CJ;Chou, IW;Li, HW;Cheng, WC;Li, TC;Cha, TL;Liao, GS;Chiu, CF;Huang, CS;Tseng, LM;Chiou, JF;Sheen-Chen, SM;Hou, MF;Hung, MC |
| 國家衛生研究院 |
2025-09-17 |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration
|
Lin, YJ;Ou, DL;Su, YY;Hsu, CL;Hsiao, CF;Ko, BS;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Jeng, YM;Lee, WC;Chou, SC;Chen, TW;Chiu, CF;Shiuan, L, Jr.;Hsieh, CH;Lee, CC;Shen, YS;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2025-06-04 |
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors
|
Chiang, NJ;Bai, LY;Ho, IW;Hsu, CH;Liang, YH;Chiu, CF;Lin, CC;Chang, KY;Chen, SH;Tsai, HJ;Lin, YP;Chen, LT;Lin, CC |
| 國家衛生研究院 |
2025-03-27 |
Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells[Erratum:Experimental and Molecular Medicine. 2024 Sep 18;56:2065-2081.]
|
Park, JM;Su, YH;Fan, CS;Chen, HH;Qiu, YK;Chen, LL;Chen, HA;Ramasamy, TS;Chang, JS;Huang, SY;Chang, WW;Lee, AY;Huang, TS;Kuo, CC;Chiu, CF |
| 國家衛生研究院 |
2025-02-10 |
FOXO3a/miR-4259-driven LDHA expression as a key mechanism of gemcitabine sensitivity in pancreatic ductal adenocarcinoma
|
Hsu, TW;Wang, WY;Chen, HA;Wang, TH;Su, CM;Liao, PH;Chen, AL;Tsai, KY;Kokotos, G;Kuo, CC;Chiu, CF;Su, YH |
| 國家衛生研究院 |
2024-09-18 |
Crosstalk between FTH1 and PYCR1 dysregulates proline metabolism and mediates cell growth in KRAS-mutant pancreatic cancer cells
|
Park, JM;Su, YH;Fan, CS;Chen, HH;Qiu, YK;Chen, LL;Chen, HA;Ramasamy, TS;Chang, JS;Huang, SY;Chang, WSW;Lee, AYL;Huang, TS;Kuo, CC;Chiu, CF |
| 國家衛生研究院 |
2024-09 |
TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S-1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
|
Su, YY;Bai, LY;Huang, CJ;Chiu, CF;Wang, HT;Du, JS;Wang, HC;Chuang, S;Shih, YH;Lin, HC;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2024-03 |
The cross-talk between FTH1 & PYCR1 plays a pivotal role in driving the progression of KRAS-mutated pancreatic cancer
|
Park, J;Qiu, YK;Su, YH;Chen, HA;Lee, AL;Chang, JS;Kuo, CC;Chiu, CF |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics
|
Chen, SC;Tsou, HHS;Lee, TY;Wang, HW;Chen, YH;Wang, TE;Su, YY;Yang, S;Chiu, CF;Liu, TW;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-09-15 |
Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chen, YY;Hsueh, SW;Yang, SH;Chiu, SC;Chiang, NJ;Chiu, TJ;Li, CP;Bai, LY;Chiu, CF;Chuang, SC;Shan, YS;Chan, DCA;Chen, LT;Yen, CJ;Peng, CM;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-09 |
A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study
|
Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT |
| 國家衛生研究院 |
2022-09 |
Organic cation transporter 2 activation enhances sensitivity to oxaliplatin in human pancreatic ductal adenocarcinoma
|
Chiu, CF;Park, JM;Chen, HH;Mau, CZ;Chen, PS;Su, YH;Chen, HA;Liu, YR;Hsieh, TH;Chiu, CC;Hung, SW;Kuo, CY;Chen, YM;Chang, CF |
| 國家衛生研究院 |
2022-08-19 |
Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer
|
Park, JM;Peng, JM;Shen, YS;Lin, CY;Hsu, TW;Su, YH;Chen, HA;Saengboonmee, C;Chang, JS;Chiu, CF;Shan, YS |
| 國家衛生研究院 |
2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study
|
Su, YY;Chiang, NJ;Li, CP;Yen, CJ;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chuang, SC;Bai, LY;Chiu, CF;Peng, CM;Chan, DC;Chiu, SC;Yang, YH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
|
Yang, SH;Chiang, NJ;Chiu, SC;Chou, WC;Bai, LY;Li, CP;Su, YY;Chiu, TJ;Chuang, SC;Peng, CM;Chan, DC;Chen, JS;Yen, CJ;Chen, YY;Chiu, CF;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma
|
Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT |
| 國家衛生研究院 |
2022-02 |
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors
|
Bai, LY;Chiang, NJ;Hsu, CH;Liang, YH;Chiu, CF;Lin, CC;Chang, KY;Chen, SH;Tsai, HJ;Lin, YP;Chen, LT;Lin, CC |
| 中山醫學大學 |
2021 |
Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer
|
Yu, AYH; Fu, RH; Hsu, SH; Chiu, CF; Fang, WH; Yeh, CA; Tang, CM; Hsieh, HH; Hung, HS |
| 中山醫學大學 |
2021 |
Delivery Capacity and Anticancer Ability of the Berberine-Loaded Gold Nanoparticles to Promote the Apoptosis Effect in Breast Cancer
|
Chiu, CF; Fu, RH; Hsu, SH; Yu, YH; Yang, SF; Tsao, TCY; Chang, KB; Yeh, CA; Tang, CM; Huang, SC; Hung, HS |
| 國家衛生研究院 |
2020-12-29 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan
|
Chen, CY;Liang, SH;Su, YY;Chiang, NJ;Wang, HC;Chiu, CF;Chen, LT;Bai, LY |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2019-11-14 |
A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue
|
Tsai, HJ;Tai, JJ;Chen, LT;Wu, MS;Yeh, KH;Lin, CW;Wang, TE;Wang, HP;Yu, FJ;Liou, JM;Hsiao, CF;Cheng, TY;Yeh, HJ;Ko, CW;Chen, MJ;Lo, GH;Hsu, PI;Chang, CS;Hwang, WS;Chuang, SS;Lee, HW;Shun, CT;Chiu, CF;Wang, WM;Hsieh, CY;Liu, TW;Lin, JT;Kuo, SH;Cheng, AL |
| 國家衛生研究院 |
2019-05 |
Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients
|
Dai, MS;Chao, TC;Chiu, CF;Lu, YS;Shiah, HS;Wu, YY;Cheng, WH;Chan, WK;Hung, T;Hung, N;Cutler, D;Kwan, R;Kramer, D;Chao, TY |
顯示項目 1-25 / 115 (共5頁)
1 2 3 4 5 > >>
每頁顯示[10|25|50]項目
|
